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increase in MACCE, validating the SYNTAX Score as prognostic factor.
Conclusion: In SYNTAX, the heart team concluded that CABG and PCI remain the
only treatment options respectively for 25% and 5% of patients. In those patients not
suitable for PCI surgical results are excellent. Patients not candidates for CABG that
underwent PCI had major co-morbidities but a satisfying outcome at three years.
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Background: The SPIRIT III trial compared the XIENCE V (Abbott Vascular, Santa
Clara, CA) everolimus-eluting stent (EES) to the TAXUS EXPRESS2 (Boston
Scientific, Natick, MA) paclitaxel-eluting stent (PES), demonstrating a statistically
significant reduction in the co-primary endpoint of angiographic in-segment late loss
at 8 months, and non-inferiority in the co-primary endpoint of target vessel failure
[TVF; cardiac death, MI, or target vessel revascularization (TVR)] at 9 months. Long-
term data are required to confirm the late safety and efficacy of the EES.
Methods: SPIRIT III was a prospective, randomized, single-blind, controlled trial that
enrolled 1002 men and women at 65 institutions in the US. Patients were randomized
2:1 to EES (n=669) vs. PES (n=333) and underwent percutaneous coronary
intervention in lesions no more than 28 mm in length with 2.5 - 3.75 mm reference
vessel diameter. Treatment of a maximum of two de novo native coronary artery
lesions, each in a different epicardial vessel was permitted. Daily dual antiplatelet
therapy included a thienopyridine for ≥6 months post-procedure and aspirin through 5
years.
Results: At 4-year follow-up, TVF occurred in 17.3% of EES patients vs. 21.2% of
PES patients (HR[95%CI] = 0.77 [0.57, 1.04], p=0.09), and MACE (cardiac death,
myocardial infarction (MI), or ischemia-driven target lesion revascularization) occurred
in 12.3% vs. 17.4% respectively, (0.66 [0.47, 0.93], p=0.02). The hazard curves
continued to diverge between 1 and 4 years. A trend towards fewer late stent thrombosis
events was observed in EES-treated subjects. The 5-year results will be available for
presentation.
Conclusion: EES compared to PES was associated with significantly improved event-
free survival at 4-years. Outcomes at 5 years, representing the longest available clinical
follow-up to date for the EES stent, will provide further insight into the long-term
safety and efficacy of EES.
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Background: The SPIRIT IV randomized trial, the largest completed trial to compare
two drug-eluting stent platforms, the XIENCE V (Abbott Vascular, Santa Clara, CA)
everolimus-eluting stent [EES] compared to the TAXUS EXPRESS2 (Boston
Scientific, Natick, MA) paclitaxel-eluting stent [PES] demonstrated significantly
reduced rates of target lesion failure (TLF) and ischemia-driven target lesion
revascularization (ID-TLR), with non-inferior rates of composite cardiac death or
target-vessel myocardial infarction (MI) through 2 years follow-up. Treatment with
EES also resulted in a significant reduction in the Academic Research Consortium-
defined rate of definite or probable stent thrombosis, and of any MI. Overall outcomes
through 3 years have not yet been reported.
Methods: In the SPIRIT IV trial, 3,687 patients were prospectively randomized 2:1 to
EES vs. PES. Patients with up to 3 de novo native coronary artery lesions (maximum
2 lesions per epicardial vessel) with length ≤28 mm and reference vessel diameter ≥2.5
mm to ≤4.25 mm were enrolled at 66 U.S. clinical sites, stratified by diabetes and
lesion complexity. To enable accurate assessment of clinical event rates, routine
angiographic follow-up was not performed. The trial was powered to demonstrate
sequential noninferiority and superiority of EES compared to PES for the primary
composite endpoint of TLF at 1 year, consisting of cardiac death, target vessel MI, or
ID-TLR.
Results: Two-year follow-up results have been presented, and 3-year results for all
patients will be available in August 2011. In addition to the overall cohort, results
through 3 years will also be reported in the large subset of patients with diabetes
mellitus (1185 randomized patients), in whom TLF rates between EES and PES were
similar at 1 and 2 years.
Conclusion: The three-year outcomes from the SPIRIT IV randomized trial will
provide important insights into the long-term absolute and relative safety and efficacy
EES and PES.
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Background: Previous studies have suggested worse outcomes following primary PCI
at US vs OUS sites, but the reasons are not clear and late follow-up has not been
available.
Methods: HORIZONS-AMI randomized 3,602 STEMI pts at 123 centers in 11
countries to Primary PCI with bivalirudin (Biv) vs UFH + GPI.
Results: US vs OUS pts had more diabetes (14.0% vs 9.4%, p=0.0002), prior MI
(13.8% vs 10.1%, p=0.003), prior CABG (5.5% vs 2.2%, p<0.0001), and renal
insufficiency (20.8% vs 15.3%, p=0.0004), were heavier (84.4 vs 80.0kg, p<0.0001)
and had worse LVEF (<40%) (20.8% vs 12.7%, p<0.0001). OUS pts had higher aspirin
use, more primary PCI and stent use, and fewer CABG. OUS pts were discharged more
often on aspirin, beta blockers, ACEI, and statins. At 3 yrs US sites had higher rates of
mortality, MACE, major bleeding and NACE (Table). After adjusting for baseline risk,
mortality, major bleeding and NACE remained significantly more frequent at US sites.
Biv compared to UFH+GPI reduced NACE to a similar extent at US sites (RR: 0.87
[0.69-1.10]) and OUS sites (RR: 0.91 [0.78-1.06]) (p for interaction = 0.76).
Three Year Event Rates: US versus OUS
Conclusion: US versus OUS pts had a higher baseline risk profile and higher rates of
adverse events and bleeding. Mortality, bleeding and NACE were significantly worse
in US pts after adjusting for baseline risk. The reasons for these differences are not
clear but could be due to unmeasured confounders, differences in the threshold for
event reporting, or valid differences in systems of care and treatment which may impact
outcomes.
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Background: The outcome of PCI in patients with acute coronary syndromes (ACS)
is conventionally judged by the occurrence of composite major adverse cardiac events
(MACE). How often these events occur following intra-procedural complications
during PCI is unknown, with few prior studies assessing the occurrence and importance
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